We take pioneering MedTech companies from first consultation to sustained growth in India — guiding you through every gateway: clinical study, commercial launch, and local manufacturing. One partner, the entire climb.
Indical MedSurg Pvt Ltd is the India-based MedTech commercialisation company majority-owned by Partisan Healthcare Advisory, its major holding company. Indical's own operations are focused on India, the Middle East and Africa — and through Partisan, Indical clients gain access to Partisan's wider global network across the USA, Europe, and Latin America.
Since our founding in 2012, we have been the trusted single-window partner for foreign MedTech companies entering India — combining regulatory expertise, clinical research, local manufacturing, and distribution under one roof. Thirteen-plus years navigating India's complex MedTech regulatory landscape means global standards, deep local expertise, and real commercial results.
Everything a foreign MedTech company needs to succeed in India — a product's actual route from first study to first sale, handled end to end.
FDA projects, fast IRB approvals, 40+ investigator sites, expert data management and medical writing — from First-in-Human studies to registries.
#1 Revenue DriverMD-15 import licensing, CDSCO submissions, complete regulatory strategy, dossier preparation, and local entity formation.
#2 Key DifferentiatorPartnership with Dolphin LifeScience (US FDA registered, ISO certified) — full ETO sterilisation and ISO Class 7 cleanroom production.
#3 Cost AdvantageExperienced sales force, KOL relationships, and Partisan's global network activate the market once approved.
#4 Market ReachGujarat's prominent medical device cluster, with free-zone duty-free import and export pathways — up to 50% manufacturing cost reduction.
A vast network of commercial channel partners, experienced sales professionals, and deep KOL relationships across every major geography.
Across CRO, regulatory, manufacturing, and distribution services, Indical partners with some of the world's most innovative medical technology companies.
CMR Surgical (Cambridge, UK) needed a trusted India partner to navigate CDSCO approvals, establish a local entity, conduct India's first-in-human robotic surgery evaluation, and activate a commercial pathway across the AMEA region — within an aggressive timeline.
Served as Authorised Indian Representative, managed all CDSCO regulatory submissions, established CMR Surgical's Indian legal entity, coordinated the first-in-human evaluation across top surgical centres, and activated the AMEA commercial distribution channel.
We understand your product, therapy area, and commercial goals for India.
Tailored India entry strategy: regulatory, clinical plan, distribution model.
NDA and service agreement executed. Scope, timelines and terms agreed.
Indical files the application to CDSCO.
If required, Indical's CRO runs India clinical evaluations or registry studies.
Product approved. Distribution activated. First sales and ongoing support.
